Oxford says vaccine has good immune response with two dose regime

LONDON, Dec 17 (Reuters) - Oxford's COVID-19 vaccine
candidate stimulates broad antibody and T cell responses and has
the best immune response when a two full-dose regime is used,
the university said, citing more detailed early stage trial
data.

The vaccine "stimulates broad antibody and T cell
functions," the university said after publishing further data
from the Phase I/II clinical trials.

"The booster doses of the vaccine are both shown to induce
stronger antibody responses than a single dose, the standard
dose/standard dose inducing the best response."

(Reporting by Alistair Smout; editing by William James)